[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544711":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":10,"centralContacts":22,"locations":28,"responsibleParty":45,"collaborators":10,"id":49,"slug":10,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Uppsala University Hospital","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with sepsis and AKI",null,[12],"Radiation: Positron emission tomography (PET)",{"label":14,"type":10,"description":10,"interventionNames":15},"Healthy controls",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"RADIATION","Positron emission tomography (PET)","Assessment of blood flow with marked water and assessment of neutrophil presence with neutrophil elastase tracer + CT",[14,9],[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Miklos Lipcsey, MD, PhD","CONTACT","+46186110000","miklos.lipcsey@uu.se",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Uppsala university hospital","RECRUITING","Uppsala","75185","Sweden",{"type":36,"coordinates":37},"Point",[38,39],17.63889,59.85882,{"lat":39,"lon":38},[42],{"name":43,"role":25,"phone":44,"phoneExt":10,"email":27},"Miklos Lipcsey, MD","+4618611000",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Miklos Lipcsey","Professor","100544711",false,"NCT06372444","Mechanisms of Acute Kidney Injury in Severe Infections","PET-AKI","Inclusion Criteria:\n\nPatients with sepsis and AKI\n\n* \\> 30 years\n* At least AKI stage 1 according to KDIGO where the last plasma creatinine is measured within 24 hours of the examination\n\nHealthy volunteers\n\n* \\> 30 years\n* No previously known kidney disease\n* Normal plasma creatinine value\n\nExclusion Criteria:\n\n* Chronic renal failure (CKD stage \\>3a) or dialysis\n* Instability in vital functions that makes PET-CT examination unsuitable\n* Claustrophobia or other reasons that make the patient unable to lie still during the examination.\n* Pregnancy and breastfeeding",true,"ALL","30 Years",{"count":59,"type":60},15,"ESTIMATED","OBSERVATIONAL","Renal perfusion and neutrophil-mediated inflammation will be assessed in the kidney in sepsis patients with acute kidney injury using positron emission tomography. For marked water will be used for renal perfusion and a newly developed PET tracer molecule (11C-GW457427) with specific binding to neutrophil elastase which provides a measure of the amount of infiltrating neutrophils in the renal parenchyma for inflammation. The study is performed in a PET-CT camera where anatomical imaging takes place at the same time as the PET examinations.",[64,65,66],"Sepsis","AKI - Acute Kidney Injury","Positron Emission Tomography (PET)","2024-12-03",{"date":69,"type":70},"2024-12-06","ACTUAL",{"date":72,"type":70},"2024-05-01",{"date":74,"type":60},"2026-06-30",{"name":5,"class":6},1]